Fmoc-L-Lys[C20-OtBu-Glu(OtBu)-AEEA-AEEA]-OH is a protected lysine derivative supplied as a pharmaceutical-grade starting material for solid-phase peptide synthesis. The molecule carries an Fmoc-protected alpha-amine, a free alpha-carboxylic acid, and an epsilon-amine side chain functionalized with a tert-butyl-protected glutamic acid spacer, two 8-amino-3,6-dioxaoctanoic acid linkers, and a C20 diacid terminus protected as a tert-butyl ester. In downstream peptide manufacturing, the monomer is incorporated at a lysine residue to introduce a long-chain fatty diacid side chain without solution-phase lipidation after peptide assembly. The building block is not directly compressed into tablets or filled into capsules in its protected form. After SPPS, cleavage, purification, and desalting, the final lipidated peptide API can be processed into oral tablet, capsule, granule, or injectable dosage forms. The downstream applications described below are therefore split across peptide synthesis, solid oral form production, injectable formulation, regulatory documentation, and analytical release. Published data for this specific C20-OtBu derivative in commercial-scale oral production is limited; the ranges cited in the following sections derive from general SPPS practice and closely related Fmoc-protected lipophilic lysine building blocks.

In a 50-L to 500-L SPPS reactor with overhead agitation and a 10–30 µm sintered filter plate, the resin-bound peptide is swollen in DMF for 30–60 min at 20–25 °C. Fmoc removal is performed with 20% piperidine in DMF for 15–20 min. The deprotection stream is drained and the UV absorbance of the dibenzofulvene-piperidine adduct is monitored at 301 nm. The resin is washed with DMF until the conductivity of the rinse falls below the predetermined endpoint. The preassembled Fmoc-Lys[C20-OtBu-Glu(OtBu)-AEEA-AEEA]-OH monomer is then activated with DIC and Oxyma. The activated solution is transferred to the reactor and coupled to the free amino group. Because the C20-OtBu group and AEEA linkers increase steric bulk, a second coupling is performed. Unreacted amino groups are capped with acetic anhydride and pyridine in DMF when single couplings cannot be extended. The peptide resin is sampled after the lipidated lysine incorporation; a small portion is cleaved and analysed by UPLC-MS to confirm molecular weight and absence of des-lipidated peptide. This step is repeated until the full protected peptide chain is assembled.

What Limits Coupling Efficiency of the Lipidated Lysine Building Block on Production Resins?

The coupling rate is governed by resin substitution, solvent penetration, and the steric volume of the C20-OtBu-Glu(OtBu)-AEEA-AEEA side chain. On Rink amide AM resin at 0.4 mmol/g, the terminal alpha-amine is accessible, but the hydrophobic C20 segment can adopt a folded conformation in DMF and reduce the effective collision frequency. At substitution levels above 0.6 mmol/g, peptide chain crowding decreases diffusion and increases deletion sequences. DIC/Oxyma activation in NMP at 35–45 °C improves coupling yield relative to ambient DMF coupling. However, heating above 45 °C for more than 1 h may trigger Fmoc beta-elimination and premature amino-group exposure. The resulting double insertion or peptide truncation is difficult to separate later by preparative HPLC. When HATU/DIPEA is used as an alternative activation system, the base concentration is maintained below 0.2 M to limit alpha-carbon racemization. Process-scale batches are sampled after the first and second coupling; residual free amine is monitored by the Kaiser test or TNBS test. The process window is narrow because low temperature preserves Fmoc stability but slows coupling, while high temperature accelerates coupling but shortens reagent half-life. For full-scale lots, the reactor jacket is set to 38 ± 2 °C, and the coupling solution is pre-activated for 3–5 min before transfer.

The TFA Cleavage Step Removes the OtBu Protecting Groups Without Cleaving the Lysine Side Chain

Global deprotection and resin cleavage are conducted with TFA-based cocktails. A common starting mixture is 95:2.5:2.5 TFA:water:triisopropylsilane, with 1–2.5% 1,2-ethanedithiol added when sulfur-containing residues are present. The cleavage time is 2–4 h at 20–25 °C. The tert-butyl esters on the glutamic acid spacer and the C20 diacid terminus are removed during this step. The C20 diacid remains attached to the lysine side chain through the AEEA linkers; cleavage of the lysine amide bond is not observed under normal conditions. Extended cleavage beyond 5 h increases formation of C20 fatty diacid-related impurities via hydrolysis of AEEA amide bonds. The crude peptide is precipitated in cold methyl tert-butyl ether at −20 to 0 °C and collected by filtration or centrifugation. Slow addition of the cleavage solution to the ether with overhead stirring at 200–400 rpm improves filterability. The precipitate is washed twice with cold ether and dried under vacuum at 25–30 °C until residual TFA is below the prescribed limit. LC-MS is used to confirm the mass shift that corresponds to removal of all tert-butyl groups and absence of residual Fmoc. Because the final peptide is hydrophobic, ether precipitation may produce a sticky solid; re-slurrying in cold ether reduces residual scavenger carryover.

Oral tablet and capsule manufacturing of the final lipidated peptide API introduces a different constraint set from parenteral production. The desalted peptide powder containing the C20 diacid side chain is cohesive at relative humidity above 60%; it is pre-dried under vacuum at 25–30 °C or stored in dry nitrogen until the moisture content is below 2.0%. Wet granulation with water is generally avoided because the AEEA linker can undergo slow hydrolysis and the peptide may aggregate. Roller compaction or slugging is preferred. The granulate is blended with mannitol, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, and sodium stearyl fumarate before compression. Tablet compression on a rotary press is run at 10–25 kN; tablet hardness is maintained at 60–120 N to allow enteric coating. For capsule filling, the granulate is filled into HPMC or gelatin capsules under controlled low humidity. The oral peptide dose typically requires an enteric coat such as poly(methacrylic acid-co-ethyl acrylate) to reduce gastric degradation. An absorption enhancer such as salcaprozate sodium may be included at product-specific ratios. Residual solvent testing is aligned to ICH Q3C, and degradation products are assessed under ICH Q3B. The final oral product is not stable under high-temperature and high-humidity storage; stability chambers are set to 25±2 °C/60% RH and 40±2 °C/75% RH according to ICH Q1A. Because the lipidated peptide can adsorb to punches and dies, cleaning and rinse swabs are monitored by UPLC-MS after each batch.

When an Injectable Lyophilized Cake Is Specified, Residual Moisture and Sterile Filtration Recovery Set the Operating Limits

For injectable dosage forms, the purified peptide API is dissolved in a pH 7.0–7.8 phosphate or histidine buffer. The peptide concentration is adjusted according to the labelled dose; subcutaneous peptide formulations commonly operate in the range of 1–10 mg/mL, but osmotic and solubility data for the specific C20 lipidated sequence must be generated. The solution is filtered through 0.22 µm PVDF or PES membrane filters into depyrogenated vials. Because the C20 fatty diacid may adsorb to filter membranes and stainless steel surfaces, recovery is checked during the filtration process. Adsorption above 2–3% of the target assay may require pre-saturating the filter with the peptide solution or reducing the filter area. The filtered solution is lyophilized using a cycle defined by freeze-drying microscopy or differential scanning calorimetry. Primary drying is performed at a chamber pressure of 50–150 µbar with shelf temperature ramps of 0.5–1.0 °C/min from −40 °C to +20 °C. The vials are stoppered under nitrogen. Residual moisture is controlled to ≤2.0% by Karl Fischer titration under USP <921>. Sterility is tested under USP <71> and bacterial endotoxins under USP <85>. Particulate matter is controlled under USP <788>. The final injectable product is protected from light and stored at 2–8 °C unless the approved stability data support a wider range.

Regulatory Dossier and Starting Material Justification for Synthetic Peptide Manufacturing

The protected lysine derivative is typically controlled as a starting material or registered intermediate under ICH Q11. The dossier must define the synthetic route, impurity profile, and carryover of unmodified Fmoc-Lys-OH, des-C20 spacer fragments, and solvent residues. Release specifications for comparable Fmoc-protected lipophilic lysine building blocks include identity by FTIR and LC-MS, chiral purity by HPLC, assay by HPLC, water content by Karl Fischer titration, residual solvents by headspace GC, and elemental impurities by ICP-MS under ICH Q3D. Residual solvents are limited under ICH Q3C, with special attention to DMF, NMP, dichloromethane, and methyl tert-butyl ether. Because upstream catalytic hydrogenation may be used in side-chain assembly, palladium content is controlled by ICP-MS under ICH Q3D; route-specific concentration limits are derived from the permitted daily exposure and the maximum daily dose of the final peptide API. The batch record should include storage in sealed, inert-gas-purged containers at −20 ± 5 °C and protection from moisture. Stability data under long-term 5±3 °C and accelerated 25±2 °C/60% RH conditions support retest or expiry assignment. Because the tert-butyl esters are acid-labile, any breach in packaging is treated as a deviation requiring immediate Karl Fischer and HPLC assay checks.

Analytical release of the Fmoc-Lys monomer before SPPS use involves reversed-phase HPLC on a C18 column with 0.1% TFA in acetonitrile/water. The C20 tail increases retention time compared with unmodified Fmoc-Lys-OH; gradient slope must be adjusted to avoid co-elution with deletion sequences. LC-MS in negative-ion mode confirms the molecular ion and detects tert-butyl loss caused by moisture. Water content is determined by Karl Fischer titration under USP <921>; GMP lots are typically released at ≤0.5% w/w. Residual piperidine, if present from upstream handling, is measured by headspace GC. Unknown impurities above 0.10% by HPLC are identified by high-resolution mass spectrometry before batch disposition. The product is stored at −20 ± 5 °C in a sealed aluminum-lined bag under nitrogen. Before weighing, the container is equilibrated to 20–25 °C to prevent condensation on the powder. The Fmoc group is not compatible with primary or secondary amines used in cleaning or buffer preparation; prolonged contact with piperidine leads to premature deprotection. The tert-butyl esters are not compatible with strong acids or aqueous acid vapors. In production warehouses, the product is segregated from volatile amines and acidic reagents.

Across Cleaning Validation and Equipment Changeover, Lipophilic Residue Retention Governs Risk

In multiproduct peptide facilities, the C20 diacid side chain of the resulting peptide intermediate leaves a lipophilic residue on stainless steel, PTFE, and EPDM gaskets. Swab sampling of reactor walls, sintered frits, transfer lines, filter housings, and lyophilizer shelves is performed after each campaign. Water alone does not reliably remove the lipophilic peptide; a mixture of dilute acetic acid and acetonitrile is used for cleaning. Rinse samples are concentrated and analysed by UPLC-MS. Health-based exposure limits are calculated from toxicological data and used to set acceptance limits for carryover. Where cleaning verification fails, the equipment is re-cleaned and re-tested before release. Campaign separation is used for high-potency peptide sequences or when the manufacturing train cannot be dedicated. The cleaning procedure must also account for the protected monomer, because residual Fmoc-Lys derivative on shared equipment can contaminate the next batch and appear as a foreign peak in the HPLC chromatogram. This facility-level control is part of the overall batch release package under 21 CFR 211.67 and ICH Q7.